A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
BUSINESS
Medicago/GSK’s COVID-19 Vaccine 71% Effective: PII/III
A plant-derived COVID-19 vaccine being developed by Medicago, a Canadian subsidiary of Mitsubishi Tanabe Pharma, using GlaxoSmithKline’s pandemic adjuvant was 71% effective against multiple variants in a placebo-controlled PII/III study, the companies said on December 7. The companies confirmed the…
To read the full story
Related Article
- Mitsubishi to Review Biz Plan around Medicago’s COVID Jab, Reexamine Japan Timeline Too
August 4, 2022
- Medicago’s COVID-19 Vaccine Approved in Canada
February 25, 2022
- Medicago Submits Final Vaccine Data for Canada’s COVID-19 Rolling Review
December 20, 2021
- Mitsubishi to Mull Domestic Manufacturing of COVID-19 Vaccine: Exec
November 4, 2021
- Medicago’s COVID-19 Vaccine Yields Positive Interim Data: PII
May 20, 2021
- Canada Starts Review of Medicago’s Rolling Submission for COVID-19 Vaccine
April 27, 2021
- Medicago/GSK Begins PIII for COVID-19 Vaccine, Mitsubishi Mum on Japan Plan
March 18, 2021
BUSINESS
- AstraZeneca, Koriyama City Team Up to Drive NCD Prevention and Early Detection
July 28, 2025
- Fuji Pharma Kicks Off Japan PIII for Alyssa in Endometriosis
July 28, 2025
- Flatiron Triples UK, Germany, Japan Oncology RWD Network in One Year
July 28, 2025
- Chugai to Defer Domestic Supply of Elevidys amid Safety Review
July 25, 2025
- Chugai to Build New Research Building to Strengthen Process Development
July 25, 2025
In the race to develop next-generation antibody therapies for solid tumors, antibody drug conjugates (ADCs) are surging, while T-cell engagers…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…